title: Herbal-drug interaction induced rhabdomyolysis in a liposarcoma patient receiving trabectedin.
abstract: BACKGROUND
  Rhabdomyolysis is an uncommon side effect of trabectedin which is used for the second line therapy of metastatic sarcoma after anthracycline and ifosfamide failure. This side effect may be due to pharmacokinetic interactions caused by shared mechanisms of metabolism involving the cytochrome P450 (CYP) system in the liver. Here, for the first time in literature, we describe the unexpected onset of heavy toxicity, including rhabdomyolysis, after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event.
  
  
  METHODS
  This is the case of a 56 year old Caucasian man affected by a relapsed de-differentiated liposarcoma who, after the fourth cycle of second-line chemotherapy with trabectedin, complained of sudden weakness, difficulty walking and diffuse muscle pain necessitating complete bed rest. Upon admission to our ward the patient showed grade (G) 4 pancytopenia and a marked increase in liver lytic enzymes, serum levels of myoglobin, creatine phosphokinase (CPK) and lactate dehydrogenase. No cardiac or kidney function injuries were present. Based on these clinical and laboratory features, our conclusive diagnosis was of rhabdomyolysis induced by trabectedin.The patient did not report any trauma or muscular overexertion and no co-morbidities were present. He had not received any drugs during treatment with trabectedin, but upon further questioning the patient informed us he had been taking a folk medicine preparation of chokeberry (Aronia melanocarpa) daily during the last course of trabectedin and in the 2 subsequent weeks.One week after hospitalization and cessation of intake of chokeberry extract, CPK and other markers of myolysis slowly returned to standard range, and the patient noted a progressive recovery of muscle strength.The patient was discharged on day 14 when a blood transfusion and parenteral hydration gradually lowered general toxicity. Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings.
  
  
  CONCLUSIONS
  The level of evidence of drug interaction leading to the adverse event observed in our patient was 2 (probable). Thus our case underlines the importance of understanding rare treatment-related toxicities such as trabectedin-induced rhabdomyolysis and the possible role of the drug-drug interactions in the pathogenesis of this rare side effect. Furthermore, this report draws attention to a potential problem of particular concern, that of nutritional supplements and complementary and alternative drug interactions. These are not widely recognized and can cause treatment failure.
authors.affiliation: Medical Oncology Department, National Cancer Research Centre Giovanni Paolo II, Bari, Italy.
authors.forename: Sabino
authors.initials: S
authors.lastname: Strippoli
authors.forename: Vito
authors.initials: V
authors.lastname: Lorusso
authors.forename: Anna
authors.initials: A
authors.lastname: Albano
authors.forename: Michele
authors.initials: M
authors.lastname: Guida
mesh_terms: D004149:Dioxoles / Q000008:administration & dosage*; D041743:Herb-Drug Interactions; D006801:Humans; D008080:Liposarcoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D046936:Photinia / Q000737:chemistry; D010936:Plant Extracts / Q000008:administration & dosage*; D012206:Rhabdomyolysis / Q000209:etiology*; D044005:Tetrahydroisoquinolines / Q000008:administration & dosage*; D000077606:Trabectedin
chemical_list: D004149:Dioxoles; D010936:Plant Extracts; D044005:Tetrahydroisoquinolines; D000077606:Trabectedin
references.citation: Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2473-6
references.pmid: 17164372
references.citation: Tumori. 2011 Mar-Apr;97(2):252-5
references.pmid: 21617727
references.citation: Invest New Drugs. 2006 Jan;24(1):3-14
references.pmid: 16379042
references.citation: Planta Med. 2008 Oct;74(13):1625-34
references.pmid: 18937167
references.citation: Phytother Res. 2009 Feb;23(2):159-64
references.pmid: 18814214
references.citation: Support Care Cancer. 2007 Jun;15(6):583-595
references.pmid: 17106659
references.citation: Case Rep Oncol. 2010 Sep;3(3):477-9
references.pmid: 21611101
references.citation: Arch Pharm Res. 2011 Apr;34(4):607-13
references.pmid: 21544726
references.citation: Basic Clin Pharmacol Toxicol. 2008 Nov;103(5):445-9
references.pmid: 18947363
references.citation: J Clin Pharmacol. 2003 Jun;43(6):643-8
references.pmid: 12817527
references.citation: J Natl Cancer Inst. 2007 Apr 18;99(8):592-600
references.pmid: 17440160
references.citation: Integr Cancer Ther. 2009 Mar;8(1):29-36
references.pmid: 19174505
references.citation: Cancer Chemother Pharmacol. 2012 Jun;69(6):1557-65
references.pmid: 22484722
references.citation: Clin Pharmacokinet. 2012 Feb 1;51(2):77-104
references.pmid: 22257149
references.citation: Nutr Cancer. 2006;54(1):84-93
references.pmid: 16800776
references.citation: J Pharmacol Exp Ther. 2000 Jul;294(1):88-95
references.pmid: 10871299
references.citation: J Nutr. 2006 Mar;136(3 Suppl):806S-809S
references.pmid: 16484569
references.citation: Adv Anat Pathol. 2009 Nov;16(6):383-91
references.pmid: 19851129
references.citation: Environ Toxicol Pharmacol. 2011 Mar;31(2):339-46
references.pmid: 21787703
references.citation: Support Care Cancer. 2010 Jul;18(7):883-91
references.pmid: 19756775
references.citation: Tumori. 2011 Mar-Apr;97(2):256
references.pmid: 21617728
references.citation: Platelets. 2008 Feb;19(1):70-7
references.pmid: 18231940
references.citation: N Engl J Med. 2005 Aug 18;353(7):701-11
references.pmid: 16107623
references.citation: J Clin Oncol. 2009 Sep 1;27(25):4188-96
references.pmid: 19652065
references.citation: Food Chem Toxicol. 2006 Sep;44(9):1572-8
references.pmid: 16762474